CN103328451B - 降低β-淀粉样物质生成的化合物 - Google Patents
降低β-淀粉样物质生成的化合物 Download PDFInfo
- Publication number
- CN103328451B CN103328451B CN201280006419.7A CN201280006419A CN103328451B CN 103328451 B CN103328451 B CN 103328451B CN 201280006419 A CN201280006419 A CN 201280006419A CN 103328451 B CN103328451 B CN 103328451B
- Authority
- CN
- China
- Prior art keywords
- dihydro
- mmol
- pyrimidine
- preparation
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C*(*)c1nc(C(CN(*C=C)C2)N)c2c(O*)n1 Chemical compound C*(*)c1nc(C(CN(*C=C)C2)N)c2c(O*)n1 0.000 description 11
- IPFZARHKKQXZPN-UHFFFAOYSA-N Clc1c(CCC2c3ccccc3)c2nc(Cl)n1 Chemical compound Clc1c(CCC2c3ccccc3)c2nc(Cl)n1 IPFZARHKKQXZPN-UHFFFAOYSA-N 0.000 description 2
- ROGBTMYYMNZACY-UHFFFAOYSA-N CC(CC1)(C(OC(N2)=O)=C1C2=O)C1=CC=CCC1 Chemical compound CC(CC1)(C(OC(N2)=O)=C1C2=O)C1=CC=CCC1 ROGBTMYYMNZACY-UHFFFAOYSA-N 0.000 description 1
- UTECHSWXONEPLI-UHFFFAOYSA-N CCNc1c(COCC2c(cc3)ccc3F)c2nc(Cl)n1 Chemical compound CCNc1c(COCC2c(cc3)ccc3F)c2nc(Cl)n1 UTECHSWXONEPLI-UHFFFAOYSA-N 0.000 description 1
- JLNXZNUKFXBSRP-UHFFFAOYSA-N CCOC(C(CN(C)CC1c(cc2)ccc2F)C1=O)=O Chemical compound CCOC(C(CN(C)CC1c(cc2)ccc2F)C1=O)=O JLNXZNUKFXBSRP-UHFFFAOYSA-N 0.000 description 1
- MUANZYIPCHDGJH-UHFFFAOYSA-N CCOC(Cc(cccc1)c1Cl)=O Chemical compound CCOC(Cc(cccc1)c1Cl)=O MUANZYIPCHDGJH-UHFFFAOYSA-N 0.000 description 1
- ISZJYKZISVOGAG-UHFFFAOYSA-N CN(C)c1c(CCC2c(cc3F)ccc3F)c2nc(Cl)n1 Chemical compound CN(C)c1c(CCC2c(cc3F)ccc3F)c2nc(Cl)n1 ISZJYKZISVOGAG-UHFFFAOYSA-N 0.000 description 1
- UQLSXFSAPXIEDP-UHFFFAOYSA-N CN(C)c1c(COCC2c3ccccc3)c2nc(Cl)n1 Chemical compound CN(C)c1c(COCC2c3ccccc3)c2nc(Cl)n1 UQLSXFSAPXIEDP-UHFFFAOYSA-N 0.000 description 1
- AKUOOEWDOSJPOF-UHFFFAOYSA-N CNc1c(CCC2c3ccccc3)c2nc(Cl)n1 Chemical compound CNc1c(CCC2c3ccccc3)c2nc(Cl)n1 AKUOOEWDOSJPOF-UHFFFAOYSA-N 0.000 description 1
- LXGDBRDXBSPNJM-UHFFFAOYSA-N CNc1c(CCCC2(c3ccccc3)O)c2nc(Cl)n1 Chemical compound CNc1c(CCCC2(c3ccccc3)O)c2nc(Cl)n1 LXGDBRDXBSPNJM-UHFFFAOYSA-N 0.000 description 1
- HVNJAMMYDKMJBD-GOSISDBHSA-N CNc1c(CC[C@@H]2c3cc(OC)ccc3)c2nc(Nc(cc2)cc(OC)c2C#N)n1 Chemical compound CNc1c(CC[C@@H]2c3cc(OC)ccc3)c2nc(Nc(cc2)cc(OC)c2C#N)n1 HVNJAMMYDKMJBD-GOSISDBHSA-N 0.000 description 1
- HVNJAMMYDKMJBD-SFHVURJKSA-N CNc1c(CC[C@H]2c3cccc(OC)c3)c2nc(Nc(cc2OC)ccc2C#N)n1 Chemical compound CNc1c(CC[C@H]2c3cccc(OC)c3)c2nc(Nc(cc2OC)ccc2C#N)n1 HVNJAMMYDKMJBD-SFHVURJKSA-N 0.000 description 1
- OAZJTZDRPXRFRU-UHFFFAOYSA-N CNc1c(CN(C)CC2c3ccccc3)c2nc(Cl)n1 Chemical compound CNc1c(CN(C)CC2c3ccccc3)c2nc(Cl)n1 OAZJTZDRPXRFRU-UHFFFAOYSA-N 0.000 description 1
- SYNHROIZVCOPNZ-UHFFFAOYSA-N COc1cccc(C2c3nc(Cl)nc(Cl)c3CC2)c1 Chemical compound COc1cccc(C2c3nc(Cl)nc(Cl)c3CC2)c1 SYNHROIZVCOPNZ-UHFFFAOYSA-N 0.000 description 1
- ADCYXHCTFWYVAZ-XLLULAGJSA-N C[C@@H](C1CC1)Nc1nc(Cl)nc2c1CCC2c(cc1)ccc1F Chemical compound C[C@@H](C1CC1)Nc1nc(Cl)nc2c1CCC2c(cc1)ccc1F ADCYXHCTFWYVAZ-XLLULAGJSA-N 0.000 description 1
- ADCYXHCTFWYVAZ-IAPIXIRKSA-N C[C@H](C1CC1)Nc1c(CCC2c(cc3)ccc3F)c2nc(Cl)n1 Chemical compound C[C@H](C1CC1)Nc1c(CCC2c(cc3)ccc3F)c2nc(Cl)n1 ADCYXHCTFWYVAZ-IAPIXIRKSA-N 0.000 description 1
- IYDMLGHOWPWQAI-IAPIXIRKSA-N C[C@H](C1CC1)Nc1c(COCC2c3ccc(C(F)(F)F)cc3)c2nc(Cl)n1 Chemical compound C[C@H](C1CC1)Nc1c(COCC2c3ccc(C(F)(F)F)cc3)c2nc(Cl)n1 IYDMLGHOWPWQAI-IAPIXIRKSA-N 0.000 description 1
- XQFIVAGSQZTUFN-UHFFFAOYSA-N Cc1cc(F)cc(F)c1C1c2nc(Cl)nc(Cl)c2CC1 Chemical compound Cc1cc(F)cc(F)c1C1c2nc(Cl)nc(Cl)c2CC1 XQFIVAGSQZTUFN-UHFFFAOYSA-N 0.000 description 1
- QJDNDIWFKOYANR-UHFFFAOYSA-N Clc1c(C2c3nc(Cl)nc(Cl)c3CC2)cccc1 Chemical compound Clc1c(C2c3nc(Cl)nc(Cl)c3CC2)cccc1 QJDNDIWFKOYANR-UHFFFAOYSA-N 0.000 description 1
- HOOLEKJOYGSXRR-UHFFFAOYSA-N Clc1c(COCC2c3ccccc3)c2nc(Cl)n1 Chemical compound Clc1c(COCC2c3ccccc3)c2nc(Cl)n1 HOOLEKJOYGSXRR-UHFFFAOYSA-N 0.000 description 1
- NOWMZGSZLHGQEI-UHFFFAOYSA-N FC(C1)(CN1c1c(CCC2c(cc3)ccc3F)c2nc(Cl)n1)F Chemical compound FC(C1)(CN1c1c(CCC2c(cc3)ccc3F)c2nc(Cl)n1)F NOWMZGSZLHGQEI-UHFFFAOYSA-N 0.000 description 1
- APUBFNXGFFOFLJ-UHFFFAOYSA-N FC(C1)(CN1c1c(COCC2c(cc3)ccc3Cl)c2nc(Cl)n1)F Chemical compound FC(C1)(CN1c1c(COCC2c(cc3)ccc3Cl)c2nc(Cl)n1)F APUBFNXGFFOFLJ-UHFFFAOYSA-N 0.000 description 1
- VRVOLMKCWQLSJL-UHFFFAOYSA-N Fc1cc(Cl)ccc1C1c2nc(Cl)nc(Cl)c2CC1 Chemical compound Fc1cc(Cl)ccc1C1c2nc(Cl)nc(Cl)c2CC1 VRVOLMKCWQLSJL-UHFFFAOYSA-N 0.000 description 1
- DGESKOFFHXRBTQ-MNOVXSKESA-N O[C@@H](CCC1)[C@H]1c1cc(F)cc(F)c1 Chemical compound O[C@@H](CCC1)[C@H]1c1cc(F)cc(F)c1 DGESKOFFHXRBTQ-MNOVXSKESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161437279P | 2011-01-28 | 2011-01-28 | |
| US61/437,279 | 2011-01-28 | ||
| PCT/US2012/022665 WO2012103297A1 (en) | 2011-01-28 | 2012-01-26 | COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103328451A CN103328451A (zh) | 2013-09-25 |
| CN103328451B true CN103328451B (zh) | 2015-06-10 |
Family
ID=45688981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280006419.7A Expired - Fee Related CN103328451B (zh) | 2011-01-28 | 2012-01-26 | 降低β-淀粉样物质生成的化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8710061B2 (enExample) |
| EP (1) | EP2668168B1 (enExample) |
| JP (1) | JP5908499B2 (enExample) |
| KR (1) | KR20140014152A (enExample) |
| CN (1) | CN103328451B (enExample) |
| AR (1) | AR084944A1 (enExample) |
| AU (1) | AU2012211301B2 (enExample) |
| BR (1) | BR112013018298A2 (enExample) |
| CA (1) | CA2825906A1 (enExample) |
| EA (1) | EA201391097A1 (enExample) |
| IL (1) | IL226677A (enExample) |
| MX (1) | MX2013008699A (enExample) |
| SG (1) | SG191840A1 (enExample) |
| TW (1) | TW201309655A (enExample) |
| WO (1) | WO2012103297A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102227271B1 (ko) | 2013-04-15 | 2021-03-12 | 에프엠씨 코포레이션 | 살진균성 아미드 |
| WO2016080516A1 (ja) * | 2014-11-21 | 2016-05-26 | 味の素株式会社 | Ｄｒｐ１重合阻害剤 |
| US10913744B2 (en) | 2015-02-13 | 2021-02-09 | Dana-Farber Cancer Institute, Inc. | LRRK2 inhibitors and methods of making and using the same |
| CN105017046A (zh) * | 2015-07-15 | 2015-11-04 | 上海博康精细化工有限公司 | 一种4-环丙胺基丁酸乙酯的制备方法 |
| US10494378B2 (en) * | 2015-07-21 | 2019-12-03 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof |
| JP7335242B2 (ja) * | 2017-11-27 | 2023-08-29 | エフ． ホフマン－ラ ロシュ アーゲー | ピリミジン誘導体 |
| WO2020156445A1 (zh) | 2019-01-29 | 2020-08-06 | 山东轩竹医药科技有限公司 | 己酮糖激酶抑制剂及其用途 |
| CN112028839B (zh) * | 2020-09-30 | 2022-04-12 | 中国海洋大学 | 一种医药中间体环烷烃并嘧啶二酮化合物的合成方法 |
| TW202317528A (zh) * | 2021-06-24 | 2023-05-01 | 美商富曼西公司 | 用於防治無脊椎有害生物的唑類化合物 |
| CN117417302A (zh) * | 2023-04-12 | 2024-01-19 | 江苏艾迪药业股份有限公司 | 艾诺韦林的制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2226315A1 (en) * | 2007-12-28 | 2010-09-08 | Carna Biosciences Inc. | 2-aminoquinazoline derivative |
| CN102548557A (zh) * | 2009-07-31 | 2012-07-04 | 百时美施贵宝公司 | 用于降低β-淀粉状蛋白生成的化合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1698627A1 (en) | 2000-09-15 | 2006-09-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| TW201030002A (en) * | 2009-01-16 | 2010-08-16 | Bristol Myers Squibb Co | Bicyclic compounds for the reduction of beta-amyloid production |
| US8637525B2 (en) * | 2009-07-31 | 2014-01-28 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
-
2012
- 2012-01-17 TW TW101101816A patent/TW201309655A/zh unknown
- 2012-01-26 BR BR112013018298A patent/BR112013018298A2/pt not_active IP Right Cessation
- 2012-01-26 JP JP2013551323A patent/JP5908499B2/ja not_active Expired - Fee Related
- 2012-01-26 SG SG2013051552A patent/SG191840A1/en unknown
- 2012-01-26 EP EP12704954.2A patent/EP2668168B1/en not_active Not-in-force
- 2012-01-26 US US13/358,822 patent/US8710061B2/en active Active
- 2012-01-26 EA EA201391097A patent/EA201391097A1/ru unknown
- 2012-01-26 CN CN201280006419.7A patent/CN103328451B/zh not_active Expired - Fee Related
- 2012-01-26 KR KR1020137022590A patent/KR20140014152A/ko not_active Withdrawn
- 2012-01-26 WO PCT/US2012/022665 patent/WO2012103297A1/en not_active Ceased
- 2012-01-26 MX MX2013008699A patent/MX2013008699A/es unknown
- 2012-01-26 AU AU2012211301A patent/AU2012211301B2/en not_active Ceased
- 2012-01-26 CA CA2825906A patent/CA2825906A1/en not_active Abandoned
- 2012-01-27 AR ARP120100283A patent/AR084944A1/es not_active Application Discontinuation
-
2013
- 2013-05-30 IL IL226677A patent/IL226677A/en not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2226315A1 (en) * | 2007-12-28 | 2010-09-08 | Carna Biosciences Inc. | 2-aminoquinazoline derivative |
| CN102548557A (zh) * | 2009-07-31 | 2012-07-04 | 百时美施贵宝公司 | 用于降低β-淀粉状蛋白生成的化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2825906A1 (en) | 2012-08-02 |
| AR084944A1 (es) | 2013-07-10 |
| US20130030011A1 (en) | 2013-01-31 |
| JP5908499B2 (ja) | 2016-04-26 |
| TW201309655A (zh) | 2013-03-01 |
| AU2012211301A1 (en) | 2013-09-19 |
| JP2014503590A (ja) | 2014-02-13 |
| US8710061B2 (en) | 2014-04-29 |
| EP2668168A1 (en) | 2013-12-04 |
| IL226677A (en) | 2014-11-30 |
| EA201391097A1 (ru) | 2013-11-29 |
| MX2013008699A (es) | 2013-08-21 |
| BR112013018298A2 (pt) | 2016-11-16 |
| WO2012103297A1 (en) | 2012-08-02 |
| EP2668168B1 (en) | 2017-03-01 |
| CN103328451A (zh) | 2013-09-25 |
| SG191840A1 (en) | 2013-08-30 |
| AU2012211301B2 (en) | 2016-02-25 |
| KR20140014152A (ko) | 2014-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102548557B (zh) | 用于降低β-淀粉状蛋白生成的化合物 | |
| CN103328451A (zh) | 降低β-淀粉样物质生成的化合物 | |
| US8637525B2 (en) | Compounds for the reduction of beta-amyloid production | |
| CN104470925B (zh) | 作为激酶抑制剂的咪唑并三嗪甲腈 | |
| CN107253963B (zh) | 吡啶酮和氮杂吡啶酮化合物及使用方法 | |
| KR20240026911A (ko) | 골수성 세포 2 작용제 상에서 발현되는 유발 수용체로서의 헤테로고리 화합물 및 사용 방법 | |
| CN110088096A (zh) | 作为泛素特异性蛋白酶7的抑制剂的哌啶衍生物 | |
| CN105431420A (zh) | 二杂芳基化合物及其用途 | |
| TW201514145A (zh) | 作為ｂｔｋ抑制劑的初級甲醯胺 | |
| CN105073715A (zh) | 二氢哒嗪-3,5-二酮衍生物 | |
| CN112135818A (zh) | 4-羟基哌啶衍生物及其作为泛素特异性蛋白酶19(usp19)的抑制剂的用途 | |
| CN113365696A (zh) | 药物化合物和其作为泛素特异性蛋白酶19(usp19)抑制剂的用途 | |
| TW202613115A (zh) | Btk降解劑及其用途 | |
| HK1212700B (en) | Dihydropyridazine-3,5-dione derivative | |
| HK1197401A (en) | Alkylated piperazine compounds as inhibitors of btk activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150610 Termination date: 20170126 |